Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
J Vasc Interv Radiol. 2024 Jun;35(6):825-833. doi: 10.1016/j.jvir.2024.03.004. Epub 2024 Mar 12.
To assess the analgesic and anxiolytic effects of virtual reality (VR) augmentation in patients undergoing peripherally inserted central catheter (PICC) placement or fine-needle aspiration thyroid biopsy.
This is a prospective, single-center randomized controlled trial with 107 patients enrolled. Patients were randomly assigned to receive standard of care (SOC) or SOC+VR during PICC or thyroid biopsy procedures. Pain and anxiety were individually measured using the visual analog scale (VAS) before and after the procedure. Vital signs including heart rate and systolic and diastolic blood pressure were recorded. One-way analysis of variance test and Games-Howell post hoc analysis were used to assess effect size and statistical significance between SOC and SOC+VR measures.
The PICC cohort consisted of 59 patients (33 in SOC+VR and 26 in SOC), with a median age of 53.1 years (interquartile range [IQR], 38.3-62.7 years). The thyroid biopsy cohort consisted of 48 patients (26 in SOC+VR and 22 in SOC), with a median age of 60.1 years (IQR, 49.0-67.2 years). One-way analysis of individuals undergoing thyroid biopsies with adjunctive VR revealed an effect size of -1.74 points (SE ± 0.71; P = .018) on VAS pain scale when compared with SOC. Analysis of individuals undergoing PICC placements revealed an effect size of -1.60 points (SE ± 0.81; P = .053) on VAS anxiety when compared with SOC.
VR as a nonpharmacologic adjunct reduced some procedure-related pain and anxiety without increasing the procedural duration.
评估虚拟现实 (VR) 增强在接受经外周中心静脉置管 (PICC) 或细针抽吸甲状腺活检患者中的镇痛和抗焦虑作用。
这是一项前瞻性、单中心随机对照试验,共纳入 107 例患者。患者在 PICC 或甲状腺活检过程中随机接受标准护理 (SOC) 或 SOC+VR。分别使用视觉模拟量表 (VAS) 在操作前后测量疼痛和焦虑程度。记录生命体征,包括心率、收缩压和舒张压。使用单因素方差分析和 Games-Howell 事后分析评估 SOC 和 SOC+VR 措施之间的效应大小和统计学意义。
PICC 队列包括 59 例患者(SOC+VR 组 33 例,SOC 组 26 例),中位年龄为 53.1 岁(四分位距 [IQR],38.3-62.7 岁)。甲状腺活检队列包括 48 例患者(SOC+VR 组 26 例,SOC 组 22 例),中位年龄为 60.1 岁(IQR,49.0-67.2 岁)。对接受附加 VR 的甲状腺活检患者进行个体分析显示,与 SOC 相比,VAS 疼痛量表的效应大小为-1.74 分(SE ± 0.71;P =.018)。对接受 PICC 置管的患者进行分析显示,与 SOC 相比,VAS 焦虑量表的效应大小为-1.60 分(SE ± 0.81;P =.053)。
VR 作为一种非药物辅助手段,可减轻一些与操作相关的疼痛和焦虑,而不会增加操作时间。